Navigation Links
'Greener' than expected
Date:8/30/2010

he total. "Lithium-ion rechargeable batteries are not as bad as previously assumed," according to Dominic Notter, coauthor of the study which has just been published in the scientific journal "Environmental Science & Technology".

The outlook is not as rosy when one looks at the operation of an electric vehicle over an expected lifetime of 150'000 kilometers. The greatest ecological impact is caused by the regular recharging of the battery, that is, the "fuel" of the e-car. "Refueling" with electricity sourced from a mixture of atomic, coal-fired and hydroelectric power stations, as is usual in Europe, results in three times as much pollution as from the Li-ion battery alone. It is therefore worth considering alternative power sources: If the electricity is generated exclusively by coal-fired power stations, the ecobalance worsens by another 13 per cent. If, on the other hand, the power is purely hydroelectric, then this figure improves by no less than 40 per cent.

The conclusion drawn by the Empa team: a petrol-engined car must consume between three and four liters per 100 kilometers (or about 70 mpg) in order to be as environmentally friendly as the e-car studied, powered with Li-ion batteries and charged with a typical European electricity mix.


'/>"/>

Contact: Dr. Dominic Notter
dominic.notter@empa.ch
41-448-234-760
Swiss Federal Laboratories for Materials Science and Technology (EMPA)
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. This grass is still greener
2. Growing greener greens
3. Genomic research will enable greener cleanup of military explosive test sites
4. UAB, partners seek safe carbon dioxide storage for greener power generation
5. Glimpsing a greener future
6. Research is vital to a cleaner, greener, low carbon future
7. Greener horizons: Plastics may grow on trees
8. Organic pesticides not always greener choice, study finds
9. Study of placenta unexpectedly leads to cancer gene
10. Unexpected finding opens up new way to stop autoimmune diseases and transplant rejection
11. New and unexpected mechanism identified how the brain responds to stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
(Date:12/3/2014)... As part of our commitment to offering ... to announce the release of a new reader that ... workforce data that they need. The Atlas ... existing readers. Many such devices have serious shortcomings when ... Older models force users to navigate numerous complicated steps ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... Rochelle, NY, December 12, 2012ExxonMobil and many other ... dollars to develop transportation biofuels from renewable resources ... microalgae. As global supplies of fossil fuels continue ... promising source of low-cost, scalable renewable energy. The ...
... painstaking effort to create a biocompatible patch to heal infant ... Hospital. The proof is in a petri dish in ... beats with the rhythm of a living heart. Jacot, ... their tissue-engineering colleagues have published the results ofyears of effort ...
... Springer and the Italian Society for Ultrasound in Medicine and ... the Journal of Ultrasound , starting in 2013 with ... is the official journal of SIUMB. It will be available ... formerly published by Elsevier. The Journal of Ultrasound ...
Cached Biology News:Can algae-derived oils support large-scale, low-cost biofuels production? 2Rice, Texas Children's team creates biocompatible patch to heal infants with birth defects 2Rice, Texas Children's team creates biocompatible patch to heal infants with birth defects 3Springer will collaborate with the Italian Society for Ultrasound in Medicine and Biology 2
(Date:12/17/2014)... 17, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... acquisition, development and commercialization of innovative therapeutics addressing cancer ... with a primary commercial focus on China ... a Type C meeting with the U.S. Food and ... held in February 2015.  During this meeting the Company ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... COPENHAGEN, Denmark , Dec. 15, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... from its ongoing Phase 2 pediatric study to ... growth hormone deficiency, or GHD.  This interim analysis ... the anticipated total enrollment in the study, completing ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 The ... million in 2013, and is expected to grow ... 2019. , Browse through the TOC of the ... industry trends and segments, with help of various ... The global DNA Microarray market consists of instrument, ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4
... INCLINE VILLAGE, Nev., Sept. 8 PDL BioPharma, ... guidance for the third quarter ended September 30, 2009 of ... third quarter of 2008. Royalty revenues are based on second ... for Synagis(R), which is marketed by MedImmune. When compared with ...
... NOVATO, Calif., Sept. 8 BioMarin Pharmaceutical Inc. (Nasdaq: ... will present a company update at the Morgan Stanley Healthcare Conference in ... , , Interested parties may access a ... the BioMarin website, www.BMRN.com . A replay of ...
... 8 Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) announced ... failure gout will be presented at the 2009 ACR/ARHP Annual Scientific ... posters will be presented during the "Treatment and Outcome" session on ... , Chronic Use of Pegloticase: Safety ...
Cached Biology Technology:PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 2PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million 3BioMarin to Present at the Morgan Stanley Healthcare Conference 2Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 2Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 3Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 4
Chlorine-36, 3.7 MBq, 100 uCi. 0.1-0.3 HCl.< 111 MBq/g Cl, < 3 mCi/g Cl.Dispensed to order. Please inquire for alternative pack sizes. Category: Radiochemicals &Radiation Safety, Radiochemicals....
Inquire...
...
... Detection Kit is intended for quantitative detection ... peptides, which can result from the gradual, ... aspartic acid residues during storage or handling. ... the monitoring of charge differences for detection, ...
Biology Products: